Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol - Wikidata - awgldk - TriplyDB

Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol

Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol

http://www.wikidata.org/entity/Q36850695

about

Natural Killer Cells for Therapy of Leukemia Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy Selection and expansion of natural killer cells for NK cell-based immunotherapy T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Manufacturing Natural Killer Cells as Medicinal Products Advantages and applications of CAR-expressing natural killer cells Understanding of molecular mechanisms in natural killer cell therapy Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.Induced Human Decidual NK-Like Cells Improve Utero-Placental Perfusion in Mice.Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation.Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections.Natural Killer Cell Immunotherapy: From Bench to Bedside Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.The antileukemic potential of natural killer cells.Advances in clinical NK cell studies: Donor selection, manufacturing and quality control Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property.Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation.Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Ex vivo expansion of human peripheral blood natural killer cells and cytotoxic T lymphocytes from lung cancer patients.

P2860

Q26745906-7F31E5CB-598E-4434-9641-182AB22F37B6 Q26771449-CF7F05D6-327B-451A-8BEA-BC629C46D6F0 Q26774777-474D15A2-0F8E-4AEC-9396-0B76889AF826 Q26826830-C37626FF-81D1-424F-A66B-B924473806F2 Q26996660-6D2E825B-B7D6-43B3-A4E4-B4EE6E61D129 Q27329648-FAAD9CD4-5F87-425F-9215-4E423D150673 Q28069992-584C7B08-C3A1-4B24-8E10-9A3F922209D8 Q28080875-A9E51163-DCA1-4D02-8086-4A083CBF336B Q28086976-7F541E2A-906B-4186-B9A6-E4547BF82BE5 Q28266580-A10510EC-E9C6-4706-AAE4-A1A6B10666D5 Q33700795-BA555261-4C5D-4533-9103-4F8EAB569A10 Q34180695-ACD2D8D9-C1F2-4C1C-BF83-6B5BE0C6B63F Q35600095-6BF942E5-840C-4C56-966C-C770CECAF5BC Q36055257-E4BE71E5-6B1E-4132-B2CC-31A002141CD8 Q36110266-7ABC2E2F-38E2-4E77-B88F-3B8A287D8567 Q36162606-D1F30D52-6986-4F52-83CF-A435124072E2 Q37525543-A23386AF-8A96-4B9A-A2BD-7BBBBCE8429D Q37634627-502A99EB-CBC2-4A4E-8F99-2A8CA9BC64C5 Q38531958-1E0BE848-D021-4138-BDE8-DB1800A41C50 Q38666579-E5DE7935-B5BB-48E5-861F-7FB18A26EB40 Q38740111-119B4C3F-D822-46A0-B778-6D00FA4DE7E7 Q38773351-93CAB79D-9E82-4551-88E5-D78D3A3DDFCB Q38824360-550E0939-F1BE-4559-9C8C-562B87C528AC Q38841469-681E40CB-B09E-4979-86CA-3EA693AF7B8C Q39296861-C928B63F-3C8D-4D3A-B881-F9E76D6F8E05 Q41097112-172EFF9B-8A8C-408A-9164-2286DDA100B2 Q41699529-2B06CE1D-1268-40EF-9A76-F665E9FCE90E Q47843897-FDA71D86-0005-44C0-9E6B-DD5388119AFC Q48590636-77B68A2A-939E-4AD7-9FC2-63BEC7973878 Q50236616-FB265D91-D0B2-403A-B04A-A96A5DB524A3 Q52645997-D6D6998D-E872-49F9-B6EC-CFDBEEF7154E Q53705286-993BAC29-0A27-4A98-9937-B01FFEBA7586 Q55211345-F1A88A97-EA87-43B0-A10B-3FEC10B053DB

P2860

Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol

http://www.wikidata.org/entity/Q36850695

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Clinical grade purification an ...... timized manufacturing protocol

@en

type

label

Clinical grade purification an ...... timized manufacturing protocol

@en

prefLabel

Clinical grade purification an ...... timized manufacturing protocol

@en

P1433

Q36850695-3688D28D-16FD-4A2E-9896-BAE45A840D74

P1476

Q36850695-8A1A3A10-220A-4882-A090-9FF732AF0070

P2093

Q36850695-0E5C13E6-2A96-4584-B436-80767EA3FE39

Q36850695-224BEC45-0118-458F-B042-9C4A95EC709E

Q36850695-447A8B6B-1ED3-490D-A8CD-0A19664F183A

Q36850695-5F8C15FD-9B1E-4D22-B21F-9864D2550B4C

Q36850695-6B5F943B-0480-4963-A117-5ED5C740C74E

Q36850695-74148C8D-FBD3-4A7D-9108-7CDA40DCFA3C

Q36850695-98911AD7-492E-49B2-A416-8279CDAF5089

Q36850695-A1065A92-42B7-484D-8A06-0C936D5E3993

Q36850695-A60A421A-7BFC-429D-853D-E00CCA544D0E

Q36850695-A75645A2-3B5F-421E-A9EB-CF222A125479

P2860

Q36850695-000B6AE3-180B-4534-BD2A-1038A3A3060E

Q36850695-02718DE9-87B7-417D-A448-60745ED216C1

Q36850695-074C326F-752D-4F86-890E-1408637DBA86

Q36850695-114D9B42-047E-418D-B233-859FC28E004D

Q36850695-1526032B-25B6-48F9-BB96-941C9B171B74

Q36850695-312B74BE-8298-4EB3-97D1-380D3192F40B

Q36850695-39B87186-D7BF-4D99-839C-EFACDCB5BCE7

Q36850695-46380219-BB56-4F35-AFFA-1A20FD9033ED

Q36850695-49409A98-5DF8-48AE-8C12-810C1F75BA06

Q36850695-4D7798E6-79C3-4525-8E59-1C7781C791A1

P304

Q36850695-F27B70F3-801F-4392-B386-DEF54392035C

P31

Q36850695-77DDABDF-7801-4899-ADCE-786610D0AE16

P356

Q36850695-BFCB5A4E-887A-4ED0-AEF2-1C4CDC278E46

P478

Q36850695-52009F82-F9DD-4F79-A9BF-410A229669E8

P50

Q36850695-0293F65A-07F0-4784-B621-E6E3AF5F5A60

Q36850695-096BA882-E14E-4E5B-B7F3-0C95ED2DE439

Q36850695-8F82A78A-5B1E-4CE4-887F-F74DA320713D

P577

Q36850695-2ABBD224-B558-4E15-BC2E-76CE9BD3FE34

P5875

Q36850695-A3ACC673-B2AE-41F7-A5A0-D68B26C8D17A

P698

Q36850695-0C673B22-E2DF-4C68-A8C4-E51AC6778F5D

P932

Q36850695-E3F59A8C-C5C3-4BC7-B881-FCDA2AC3BF10

P356

FONC.2013.00118

P1433

Frontiers in Oncology

P1476

Clinical grade purification an ...... timized manufacturing protocol

@en

P2093

Andrea Quaiser

http://www.w3.org/2001/XMLSchema#string

Christian Seidl

http://www.w3.org/2001/XMLSchema#string

Claudia Brehm

http://www.w3.org/2001/XMLSchema#string

Claudia Wunram

http://www.w3.org/2001/XMLSchema#string

Dirk Schwabe

http://www.w3.org/2001/XMLSchema#string

Eileen Auth

http://www.w3.org/2001/XMLSchema#string

Jakob Passweg

http://www.w3.org/2001/XMLSchema#string

Jan Soerensen

http://www.w3.org/2001/XMLSchema#string

Martin Stern

http://www.w3.org/2001/XMLSchema#string

Melanie Bremm

http://www.w3.org/2001/XMLSchema#string

P2860

High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy

Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands

NK cell recognition

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.

P304

118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2013.00118

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Klingebiel

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237014918

http://www.w3.org/2001/XMLSchema#string

P698

23730623

http://www.w3.org/2001/XMLSchema#string

P932

3656406

http://www.w3.org/2001/XMLSchema#string